NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

NanoViricides, Inc. (NYSE American: NNVC) , a clinical-stage innovator in broad-spectrum antivirals, announced near-finalization of its adaptive clin ...

NanoViricides, Inc. is a publicly traded clinical-stage company focused on creating special purpose nanomaterials for antiviral therapy. The company's innovative nanoviricide class of drug candidates ...

The Director-General of the World Health Organization (WHO) is hereby transmitting the report of the fourth meeting of the International Health Regulations (2005) (IHR) Emergency Committee (Committee) ...

An analysis of mpox virus genomes from individuals infected between 2018 and 2023 has provided insights into how the virus ...

As of 17 June 2025, there have been over 4,000 confirmed cases of mpox and 25 deaths in Sierra Leone, raising the possibility that the virus will spread to neighbouring countries and spark a larger ...

NNVC NanoViricides, Inc. (NYSE:NNVC) is a clinical-stage biopharmaceutical company developing a new class of broad-spectrum ...

SHELTON, CONNECTICUT / ACCESS Newswire / July 16, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the ...

This report describes three cases of clade Ib MPXV infection in pregnant women (one in each trimester of gestation) with molecular and histopathological evidence of transplacental transmission.

Researchers have provided more evidence that mpox virus can be passed from a pregnant mother to her child. There remain limited data about vertical transmission of mpox from mother to baby, but ...

There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate ...